Skip to main content
. 2017 Mar 9;7:44123. doi: 10.1038/srep44123

Figure 5. CTCE-NPs loaded with sorafenib and the MEK inhibitor AZD6244 suppressed angiogenesis in HCC.

Figure 5

(a) The tissue distribution of C6 in different formulations was measured by a plate reader at excitation wavelength 485 nm and emission wavelength 538 nm (n = 7–10). (b) The intracellular tumor uptake of C6 in different formulations 4 h after intravenous administration was imaged by a confocal microscopy. (c) CTCE-NPs containing sorafenib and AZD6244 significantly decreased activation of ERK induced by sorafenib treatment. (d,e) Sorafenib and AZD6244 co-delivered by CTCE-NPs significantly reduced the mean vessel density in HCA-1 tumors of orthotopic HCC-bearing mice (n = 6–12). Data are representative of at least two independent experiments and mean values and S.E.M. are presented. *p < 0.05, **p < 0.01, ***p < 0.001.